As of December 2013, Novozymes had roughly 49,000 shareholders, of which ~99% were private investors, mainly in Denmark. Twenty institutional shareholders, including Novo A/S, owned approximately 60% of the B stock. Investors outside Denmark hold approximately 65% of the B common stock.
As of December 2013 Novo A/S held 26% of the total outstanding common stock and controlled 71% of the votes through its holding of the A common stock and 29,131,400 B shares. Novo A/S is wholly owned by the Novo Nordisk Foundation, and so Novozymes is included in the consolidated financial statements of the Novo Nordisk Foundation. Novo A/S is domiciled in Hellerup, Denmark.
Only two shareholders, Novo A/S and Baillie Gifford & Co., currently hold more than 5% of the total common stock.